Supporting patients with advanced or high-risk disease is emotional and stressful for both patients and specialist nurses. Having a treatment guide close at hand can simplify explanations and give people something to refer to over the longer-term.
Relugolix (ORGOVYX®) is prescribed to a range of men with prostate cancer:
- Adult patients with advanced hormone-sensitive prostate cancer1
- High-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy1
- High-risk localised and locally advanced hormone dependent prostate cancer as a neo-adjuvant treatment prior to radiotherapy1
On Accord Engage, you can download an essential guide for your patients on relugolix oral ADT. This booklet covers the fundamentals of the condition and how this treatment works. Frequently asked questions on symptoms and side effects are also answered.1
Ensure that all your relugolix patients get their copy.
Please refer to the SmPC for a full list of adverse events associated with ORGOVYX®▼ (relugolix) therapy.
More articles and presentations
Introducing Orgovyx®
Read more
The Unmentionables: Podcast
Podcast series hosted by Jeff Stelling helping people to talk openly about what matters most in prostate cancer. This podcast is for people diagnosed with prostate cancer and their families.
Listen Here
Medical Education
Read moreReference:
- ORGOVYX® Summary of Product Characteristics.
Abbreviations:
ADT, androgen deprivation therapy
CV, cardiovascular
CVD, cardiovascular disease
GnRH, gonadotropin-releasing hormone
IPSS, international prostate symptom score
LHRH, luteinizing-hormone releasing hormone
LUTS, lower urinary tract symptoms
MDT, multidisciplinary team
PSA, prostate specific antigen
SHBG, sex hormone binding globulin